With the increasingly stringent requirements of international standards for the stability of clinical samples,there has been a significant rise in clinical laboratories'demand for sample stability research.To ensure the accuracy of laboratory test results,conducting research and verification work related to sample stability has become particularly urgent.However,there is currently a lack of unified standards for clinical sample stability studies both domestically and internationally.In order to better promote the resach and validation of sample stability in clinical laboratroy projects,this review summarized the latest progress in sample stability research methods by reviewing relevant literature and guidelines.It recommends referencing guidance from international organizations in clinical sample stability studies,such as the cress checklist for reporting stability studies and the"recommendations for the design of stability studies for clinical samples"issued by the European Federation of Clinical Chemistry and Laboratory Medicine(EFLM).Laboratories should select either continuous experimental design or discrete experimental design based on their practical circumstances when conducting such research.

With the increasingly stringent requirements of international standards for the stability of clinical samples,there has been a significant rise in clinical laboratories'demand for sample stability research.To ensure the accuracy of laboratory test results,conducting research and verification work related to sample stability has become particularly urgent.However,there is currently a lack of unified standards for clinical sample stability studies both domestically and internationally.In order to better promote the resach and validation of sample stability in clinical laboratroy projects,this review summarized the latest progress in sample stability research methods by reviewing relevant literature and guidelines.It recommends referencing guidance from international organizations in clinical sample stability studies,such as the cress checklist for reporting stability studies and the"recommendations for the design of stability studies for clinical samples"issued by the European Federation of Clinical Chemistry and Laboratory Medicine(EFLM).Laboratories should select either continuous experimental design or discrete experimental design based on their practical circumstances when conducting such research.

Objective To investigate short-term clinical efficacy of autologous leukocyte-poor platelet-rich plasma(LP-PRP)treatment of knee osteoarthritis(KO A).Methods 85 cases of patients with Keligren Lawrence grade Ⅰ-Ⅲ knee os-teoarthritis in Peking University First Hospital Taiyuan Hospital(Taiyuan Central Hospital)from 2022 to 2023 were collect-ed for autologous LP-PRP collection and quality assessment using a blood component separator,and all patients were treated with autologous LP-PRP.The degree and function of knee pain were assessed by visual analog scale(VAS)and knee arthri-tis index scale(WOMAC)at 1,3 and 6 months after injection.Knee MRI was performed after 6 months of treatment,and the MRI imaging changes before and after treatment were compared.Different influencing factors in the treatment results were grouped and analyzed,mainly including platelet concentration in LP-PRP and K-L grading of knee joint.According to the platelet concentration in LP-PRP,it was divided into three grades,which are low concentration[(＜800)×109/L],medium concentration[(800-1 000)×109/L],and high concentration[(＞1 000)× 109/L];According to the K-L grade of the knee joint,the severity of knee osteoarthritis was divided into three grades:Ⅰ、Ⅱ、Ⅲ.Results The VAS and WOMAC scores at 1,3 and 6 months after LP-PRP treatment were significantly lower than those before treatment,and the difference was sta-tistically significant(P＜0.05).There was a statistically significant difference in the therapeutic effect of different levels of platelet concentration,and when the platelet concentration was more than 1 000×109/L,the significant effect was the most obvious(P＜0.05).The therapeutic effect of different levels of platelet concentration was statistically significant(P＜0.05).MRI showed that the articular cartilage signal was significantly improved after treatment.Conclusion Autologous LP-PRP injection into knee cavity for the treatment of KO A has a good short-term clinical effect in relieving knee pain.

Rheumatoid arthritis(RA)and myasthenia gravis(MG)are two distinct autoimmune diseases.Compared with the general population,the incidence of RA is notably higher among patients with MG.Similarly,the rate of MG in patients diagnosed with RA is also significantly increased.In this report,we presented an elderly female patient with a history usage of long-term glucocorticoid and con-ventional synthetic disease-modifying antirheumatic drugs(csDMARDs),whose RA symptoms remained inadequately controlled.She later exhibited drooping of the right eyelid and double vision,leading to a diagnosis of ocular myasthenia gravis(OMG).Then,we made a literature review and found that the RA patients with co-existing MG were relatively more common in middle-aged and elderly women,and most of them did not have thymoma.Thymoma wasn't found in our patient,which was consistent with the cli-nical characteristics of RA complicated with MG reported in previous reports.In addition,there was li-mited treatment experience in patients with both RA and MG.The treatment stratergies for RA or MG in-cluded glucocorticoids and immunosuppressants.Among the 18 patients we analyzed,8 patients expe-rienced relief after csDMARDs,while other 8 patients received biologics or targeted DMARDs,including tumor necrosis factor inhibitors(TNFi)in 5 cases,JAK inhibitors in 2 cases,and B-cell depletion thera-py(rituximab)in 2 cases.What called for special attention was that one RA patient was diagnosed with MG after using 23 months of methotrexate and 6 weeks of etanercept(TNFi),with rituximab 1 000 mg for the first time,followed by 500 mg every 6 months,and finally both RA and MG were well controlled.For the patient in this study,MG symptoms improved with increased dosage of prednisone.In order to tapper the dose of glucocorticoid,it was necessary for more potent immunosuppressant for both RA and MG.Given her history of cardiac conditions,JAK inhibitors were not considered,and due to the uncer-tain efficacy of TNFi,we chose to administer low-dose rituximab(100 mg).Subsequent follow-up re-vealed stable conditions for both RA and MG,allowing for discontinuance of glucocorticoid after 5 months.It reflected the potential efficacy and cost-effectiveness of low-dose,long-interval rituximab in treating RA patients combined with MG,while it also minimized infection risks.However,the duration for subsequent infusions remained uncertain and required further observation.In conclusion,RA com-bined with MG is rare.For patients exhibiting poor responses to csDMARDs,low-dose,long-interval rituximab might be a promising treatment option.

Objective To study the protective effect of Shengxian decoction and the single herb decoction against myocardial injury induced by hypoxia/reoxygenation. Methods The H9c2 cells were cultured to establish hypoxia/reoxygenation model. Rats were divided into 8 groups: normal control group, hypoxia/reoxygenation group (model group) and treated groups (Shengxian decoction and the single herb decoction). The apoptotic rate of cardiomyocytes, the activity of reactive oxygen species (ROS) and intracellular calcium concentration (Ca²⁺) were measured. Results Compared with hypoxia/reoxygenation group, the apoptosis rate, ROS activity and intracellular Ca²⁺ concentration were significantly lower in all treated groups (P<0.05). The ROS activity and intracellular Ca²⁺ concentration was decreased by 41.37% and 15.20% in Shengxian decoction group compared to the model group. Conclusion Shengxian decoction and the single herb decoction had protective effect on myocardial injury induced by hypoxia/reoxygenation.